oral semaglutide cardiovascular outcomes soul trial results 2024 2025 PDF) Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized PDF) Oral Semaglutide and Cardiovascular

People who took higher doses saw their overall metabolic health get better

Similarly, there are reports of patients with psoriasis and metabolic syndrome being treated with GLP-1 receptor agonists in clinical practice, with some suggesting potential improvements in inflammatory markers, though causality cannot be established from these observations

Because these are powerful medications, they are strictly FDA-approved for chronic weight management in specific populations

Cons It is a once-daily pill

In the long term, while the immediate costs of providing access to GLP-1s may be high, the potential savings from preventing obesity-related diseases could offset these costs